Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone919-636-4530
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions
What is Fennec Pharmaceuticals' stock symbol?
Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."
How were Fennec Pharmaceuticals' earnings last quarter?
Fennec Pharmaceuticals Inc (NASDAQ:FENC) announced its quarterly earnings results on Friday, August, 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.10. View Fennec Pharmaceuticals' Earnings History.
When is Fennec Pharmaceuticals' next earnings date?
What price target have analysts set for FENC?
2 brokerages have issued 1-year target prices for Fennec Pharmaceuticals' stock. Their predictions range from $16.00 to $17.00. On average, they anticipate Fennec Pharmaceuticals' share price to reach $16.50 in the next twelve months. This suggests a possible upside of 275.0% from the stock's current price. View Analyst Price Targets for Fennec Pharmaceuticals.
What is the consensus analysts' recommendation for Fennec Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fennec Pharmaceuticals.
What are Wall Street analysts saying about Fennec Pharmaceuticals stock?
Here are some recent quotes from research analysts about Fennec Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States. " (10/14/2019)
- 2. HC Wainwright analysts commented, "In our view, PEDMARK is worth roughly $430M to Fennec based on a risk-adjusted net present value (NPV) calculation that employs a 12% discount rate, 85% probability of success and a 26% effective tax rate." (12/10/2018)
Has Fennec Pharmaceuticals been receiving favorable news coverage?
News stories about FENC stock have trended very negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Fennec Pharmaceuticals.
Who are some of Fennec Pharmaceuticals' key competitors?
Some companies that are related to Fennec Pharmaceuticals include Adverum Biotechnologies (ADVM), Harpoon Therapeutics (HARP), Gritstone Oncology (GRTS), CASI Pharmaceuticals (CASI), Cellular Biomedicine Group (CBMG), Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), PDL BioPharma (PDLI), Eiger Biopharmaceuticals (EIGR), ADMA Biologics (ADMA), LogicBio Therapeutics (LOGC), La Jolla Pharmaceutical (LJPC), Sutro Biopharma (STRO), Compugen (CGEN) and Dyadic International (DYAI).
What other stocks do shareholders of Fennec Pharmaceuticals own?
Who are Fennec Pharmaceuticals' key executives?
Fennec Pharmaceuticals' management team includes the folowing people:
- Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
- Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
- Mr. Mark Gowland, Controller
- Mr. Lei Fang, Pres of Pharstat Inc
- Ms. Anne McKay, Regulatory Consultant (Age 64)
How do I buy shares of Fennec Pharmaceuticals?
Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Fennec Pharmaceuticals' stock price today?
One share of FENC stock can currently be purchased for approximately $4.40.
How big of a company is Fennec Pharmaceuticals?
What is Fennec Pharmaceuticals' official website?
How can I contact Fennec Pharmaceuticals?
Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.
MarketBeat Community Rating for Fennec Pharmaceuticals (NASDAQ FENC)
MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote "Outperform" if you believe FENC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days.
